Mousse of Brussels sprouts and onions topped with nutmeg
Recipes & Nutrition
Author: Yves MeersmanPublished: 28 April 2016
Prep: 20 minCook: 45 minServes: 4
Brussels sprouts have a sweet, nutty flavour and are a good source iron, potassium and vitamin C. Blending them into a mousse gives them a soft and exciting texture, so it’s great for people with chewing or swallowing problems
600g Brussels sprouts (fresh or frozen)
1 tbsp baking margarine (fluid) 1 tbsp chopped chervil (fresh or frozen) 120ml vegetable stock
salt and pepper
1. Preheat the oven to 140-150 °C.
2. Peel the onion and cut into rings.
3. Remove outer leaves of the sprouts along with hard stem.
4. Make a star-shaped incision in the stems with a sharp knife.
5. If using frozen sprouts, defrost the sprouts only halfway
1. Boil the sprouts and onion rings in lightly salted water or vegetable stock.
2. Drain and reserve part of the cooking liquid.
3. Rinse the sprouts under cold running water to keep the green colour.
4. Purée the sprouts and onion together with a hand blender until smooth.
5. Put the eggs, soft margarine and vegetable stock in a mixing bowl and stir well.
6. Add the puréed sprouts and stir the mixture well until smooth
7. Season with nutmeg, salt, pepper and the finely chopped chervil.
8. Line a small, round springform tin with baking paper, fill with the Brussels sprouts mousse until almost full and cover with tinfoil.
Place the tin in the centre of the oven and bake for 40-45 minutes.
Add some cooking liquid from the sprouts when pureeing if the consistency gets too dry.
The mousse is cooked when no batter sticks to a piercer when probed.
Put the springform tin on a plate or a round saucer, remove the foil and open the fastening.
Adjusting for chewing and swallowing problems
Level 6 – use the mixture as prepared.
Level 5, 4, 3 – mix again and dilute with vegetable stock until the right consistency is reached.
If the mixture has not become smooth, heat the mousse again, moisten, bind and mix until smooth.
“There is nothing wrong with my head and I will not be judged by my condition”
The latest in our monthly series
2 days ago
Wearable device for Parkinson’s disease raises $10m in funding
UK-based tech company Charco Neurotech has secured $10 million in seed investment funding to support the launch of a non-invasive wearable device designed for people with Parkinson’s disease. CUE1 is a circular device worn on the sternum, which is designed to help alleviate Parkinson’s symptoms through specialised vibrations that are personalised for each patient. The investment round, which was co-led by venture capital company Amadeus Capital Partners and growth fund managers Parkwalk Advisors, is the largest European seed financing in 2021 for a heath technology device – and the sixth largest globally. Lucy Jung, co-founder and CEO of Charco Neurotech, said: “This funding will enable us to proceed with our first, limited launch, while we work to ensure our manufacturing line is robust and produces consistent high quality devices.” Charco also recently announced a new partnership with the European Parkinson’s Disease Association (EPDA), to help increase the availability of Charco’s…
An international team led by the University of Ottawa in Canada will study whether the scent-processing nerves inside the nose may play a part in the development of Parkinson’s disease. The researchers will explore potential connections between inflammation, environmental exposures in the nasal cavity, odour processing centres in the brain and Parkinson’s-related genes. The scientists hope that if the study indicates that Parkinson’s starts in the nose, early signs of the condition could potentially be detected sooner. This research, which will use human and animal models, has been made possible by a US $9m grant from the Aligning Science Across Parkinson’s (ASAP) initiative, which aims to improve understanding of the causes of the condition. “This grant will allow us to explore an understudied but important aspect of Parkinson’s, which could lead to new approaches for early treatment and prevention,” said Professor Michael Schlossmacher, team leader of the study.
Study finds gene therapy may restore effects of Parkinson’s drug
Levodopa is a drug commonly used to treat Parkinson’s as it helps to increase dopamine levels in the brain and improve problems with movement. In later stages of the condition, however, this treatment can become less effective. Now, findings from a US preclinical study have suggested that a new gene therapy may help to restore the effects of levodopa in people with the condition. The researchers used mice models of Parkinson’s to test the effects of the gene therapy, targeting a small region in the brain where dopamine-releasing neurons are present. They found that the therapy increased the neurons’ ability to convert levodopa to dopamine – and discovered that damage to the mitochondria in dopamine-releasing neurons may be enough to trigger Parkinson’s onset. The scientists hope their findings will encourage the development of therapies to preserve the function of these neurons, and support patients in the later stages of Parkinson’s.